FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL								
	OMB Number: 3235-028 Estimated average burden								
	hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Booth Bruce				2. Issuer Name and Ticker or Trading Symbol Magenta Therapeutics, Inc. [MGTA]					(Che	Relationship of Reporting Perso (Check all applicable) X Director			Issuer Owner			
(Last)	`	irst) IERAPEUTICS,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/05/2020						Officer below)	(give title	Othe belo	r (specify w)		
100 TECHNOLOGY SQUARE				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	IDGE M	A	02139									X Form fi	led by More	Reporting Pe		
(City)	(S	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Transactior ate Ionth/Day/Yo	Execution Date,		Code (Instr. 5)		ed (A) or tr. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	s ally ollowing	6. Ownership Form: Direct (D) or Indirec (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	perivative Conversion Date Execution Date, if any		Code (saction e (Instr. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		Owners Form: Direct (or Indir (I) (Inst	Beneficial Ownership ect (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$9.99	06/05/2020		A		18,188		(1)	06/04/2030	Common Stock	18,188	\$0.00	18,188	D ⁽²⁾		

Explanation of Responses:

- 1. This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders.
- 2. This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Remarks:

/s/ Ommer Chohan, Attorneyin-Fact for Bruce Booth

06/09/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.